Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $1.44 Million Registered Direct Offering
Press Release – New York, NY – April 23, 2020 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 722,502 American Depositary Shares (ADSs), each representing 600 of the Company’s ordinary shares, at a purchase price of $2.00 per ADS.
The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.
The Sichenzia Ross Ference LLP team was led by partners Darrin Ocasio and Avital Perlman, counsel Jeff Cahlon, and associate Yian Pan.
- Sichenzia Ross Ference LLP Represents Spartan Capital Securities LLC and Pacific Century Securities LLC in $14.1 Million Initial Public Offering of Common Shares of Lytus Technologies Holdings PTV. Ltd. - June 22, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $10 Million Private Placement of SciSparc Ltd. - June 2, 2022
- Sichenzia Ross Ference LLP Represents The Singing Machine, Inc., in $4 Million Underwritten Public Offering and Uplisting to Nasdaq - May 26, 2022